B.Riley Keeps Buy on Cytokinetics as Myqorzo Hits Market with Streamlined REMS
B.Riley reaffirmed a Buy rating and a $108 price target on Cytokinetics (CYTK), pointing to Myqorzo's potential to take share in the cardiac myosin inhibitor category. The firm's thesis rests on strong market uptake for Bristol Myers Squibb's Camzyos, Myqorzo's simplified REMS and operational advantages, and an addressable patient pool that could a…